Veru Announces Proposed Public Offering of Common Stock
February 17 2021 - 4:01PM
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company
with a focus on developing novel medicines for the management of
prostate and breast cancer, announced today that it intends to
offer and sell, subject to market conditions, shares of its common
stock in an underwritten public offering. Veru intends to grant the
underwriters a 30-day option to purchase up to an additional 15% of
the shares of its common stock offered in the public offering. The
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Jefferies is acting as the sole book-running manager for the
offering.
Veru intends to use the net proceeds of the proposed offering
for research and development, clinical trial, regulatory, and sales
and marketing expenditures, and for working capital and other
general corporate purposes.
The offering is being made by Veru pursuant to a shelf
registration statement on Form S-3 previously filed with the
Securities and Exchange Commission (SEC) on June 26, 2020 and
declared effective by the SEC on July 1, 2020. The offering will be
made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement. A
preliminary prospectus supplement and accompanying prospectus
related to the offering will be filed with the SEC and will be
available on the website of the SEC at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to the proposed offering may also be obtained by
contacting Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York,
NY 10022, by telephone at (877) 821-7388 or by e-mail
at prospectus_department@jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
any securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Veru Inc.Veru Inc. is an oncology
biopharmaceutical company with a focus on developing novel
medicines for the management of prostate and breast cancer.
Cautionary Statement on Forward Looking
StatementsThis press release contains "forward-looking
statements" as that term is defined in the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this
press release can be identified by the use of forward-looking words
or phrases such as "anticipate," "believe," "could," "expect, "
"intend," "may," "opportunity," "plan," "predict," "potential,"
"estimate," "should, " "will," "would" or the negative of these
terms or other words of similar meaning. Any forward-looking
statements in this press release are based upon current plans and
strategies of Veru Inc. (the Company) and reflect the Company's
current assessment of the risks and uncertainties related to its
business and are made as of the date of this press release. The
Company assumes no obligation to update any forward-looking
statements contained in this press release because of new
information or future events, developments or circumstances. Such
forward-looking statements are subject to known and unknown risks,
uncertainties and assumptions, and if any such risks or
uncertainties materialize or if any of the assumptions prove
incorrect, our actual results could differ materially from those
expressed or implied by such statements. Factors that may cause
actual results to differ materially from those contemplated by such
forward-looking statements include, but are not limited to,
uncertainties related to market conditions and the satisfaction of
customary closing conditions related to the proposed public
offering and the Company’s expectations regarding the completion,
timing and size of the proposed public offering and the use of
proceeds therefrom. This list is not exhaustive and other risks are
detailed in the Company’s periodic reports filed with the SEC,
including the Company's Form 10-K for the year ended September 30,
2020 and subsequent quarterly reports on Form 10-Q, which are
available at www.sec.gov.
Contact:
Sam Fisch800-972-0538 Director of Investor
Relations
Veru (NASDAQ:VERU)
Historical Stock Chart
From Aug 2024 to Sep 2024
Veru (NASDAQ:VERU)
Historical Stock Chart
From Sep 2023 to Sep 2024